Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
Academic Article
Overview
MeSH Major
Enzyme Inhibitors
Isocitrate Dehydrogenase
Leukemia, Myeloid, Acute
abstract
In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02074839 .).